Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

Abstract:

:Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.

journal_name

Drugs

journal_title

Drugs

authors

Aprile G,Bonotto M,Ongaro E,Pozzo C,Giuliani F

doi

10.1007/s40265-013-0154-8

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

2003-15

issue

18

eissn

0012-6667

issn

1179-1950

journal_volume

73

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00

  • Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.

    abstract::Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting alpha-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks. Clinical trials have demonstrated that acarbose generally improves glycaemic control ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346060-00007

    authors: Balfour JA,McTavish D

    更新日期:1993-12-01 00:00:00

  • Diabetic gastroparesis. A critical reappraisal of new treatment strategies.

    abstract::Delayed gastric emptying, gastroparesis, is one of the sequelae of diabetes mellitus. Symptoms may include postprandial nausea, epigastric pain, bloating, vomiting, early satiety and unpredictable blood sugar fluctuations. Nowadays diagnosis is made by the measurement of gastric emptying with a radionuclide test meal....

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-199244040-00002

    authors: Drenth JP,Engels LG

    更新日期:1992-10-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Bromocriptine in the treatment of hypogonadism and male impotence.

    abstract::A rapid, practical diagnostic scheme is the key to selecting proper candidates for treatment with bromocriptine. The evaluation centres around assays for prolactin and follicle stimulating hormone, polytomography and computerised axial tomography of the sella turcica and parasellar regions, and the ergot alkaloid, bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197917050-00004

    authors: March CM

    更新日期:1979-05-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

    abstract::Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464160-00003

    authors: DiFrancesco D,Camm JA

    更新日期:2004-01-01 00:00:00

  • Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity.

    abstract::Childhood obesity has become the most common paediatric disorder in the developed world. Treatment of obesity in children may include lifestyle interventions, pharmacotherapy and weight-loss supplements. The outcome of lifestyle interventions, which classically include dietary modifications, increased activity and beh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11319210-000000000-00000

    authors: Rogovik AL,Chanoine JP,Goldman RD

    更新日期:2010-02-12 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.

    abstract::Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01459-w

    authors: Rohrberg KS,Lassen U

    更新日期:2021-01-05 00:00:00

  • Lumasiran: First Approval.

    abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01463-0

    authors: Scott LJ,Keam SJ

    更新日期:2021-01-06 00:00:00

  • Rilpivirine.

    abstract::Rilpivirine is an orally administered, non-nucleoside reverse transcriptase inhibitor that is a component drug in combination therapy for antiretroviral-naive patients with HIV-1 infection. The randomized, double-blind, double-dummy, multinational ECHO and THRIVE trials in antiretroviral-naive adult patients with HIV-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208590-000000000-00000

    authors: Sanford M

    更新日期:2012-03-05 00:00:00

  • Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

    abstract::Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a lar...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0425-7

    authors: De Luca G,Savonitto S,van't Hof AW,Suryapranata H

    更新日期:2015-07-01 00:00:00

  • The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample.

    abstract::All male inhabitants of the city of Göteborg, who were born between 1915-1922 and 1924-1925 were included in the trial, and were 47 to 55 years of age on entry to the study in 1970 to 1973. One-third of these men were randomly allocated to an intervention group, whilst the other two-thirds acted as controls. Men of al...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198600311-00009

    authors: Wilhelmsen L,Berglund G,Elmfeldt D,Samuelsson O,Svardsudd K

    更新日期:1986-01-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0033-3

    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

    abstract::Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714050-00002

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-11-01 00:00:00

  • Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

    abstract::The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00012

    authors: Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

    更新日期:1985-01-01 00:00:00

  • Suicide and antidepressants.

    abstract::Depression is associated with a risk of suicide 13 to 30 times greater than in the general population, and antidepressants are among the drugs most frequently implicated in fatal overdose, resulting in a dilemma for the clinician. Suicidal thoughts are a core symptom of depression, and there is evidence that the selec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199200432-00005

    authors: Montgomery SA

    更新日期:1992-01-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549030-00002

    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • Desirable therapeutic characteristics of an optimal antihypertensive agent.

    abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666090-00006

    authors: Mustone Alexander L

    更新日期:2006-01-01 00:00:00

  • Effects of alpha-adrenoceptor blockers on renal function and blood pressure adjustment in human hypertension.

    abstract::In this paper the different aspects of the role played by alpha-adrenoceptors in the control of renin secretion from the juxtaglomerular apparatus and renal sodium and water reabsorption, and the effects of alpha-adrenoceptor antagonists on systemic haemodynamics, will be investigated. Animal experiments suggest that ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00007

    authors: Leonetti G

    更新日期:1988-01-01 00:00:00

  • Optimum management of postoperative pain.

    abstract::After surgery, patients try to minimise discomfort by various manoeuvres including change of posture, immobilisation of injured areas and use of analgesic drugs. The characteristic finding with drug use, revealed by permitting patients to titrate themselves with analgesic from a machine, is that the interindividual do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529040-00004

    authors: Bullingham RE

    更新日期:1985-04-01 00:00:00

  • Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

    abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01120-1

    authors: Heo YA,Syed YY,Keam SJ

    更新日期:2019-05-01 00:00:00

  • Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.

    abstract::Outpatient parenteral antibiotic therapy (OPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations. Inclusion criteria for patient selection for OPAT include good clinical appearance and uncomplicated infection. By virtue of their favourable microbiological...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059003-00003

    authors: Esposito S

    更新日期:2000-01-01 00:00:00

  • Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

    abstract::Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. C...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01387-9

    authors: Giménez-Arnau AM,Salman A

    更新日期:2020-11-01 00:00:00

  • New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

    abstract::Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conven...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0301-x

    authors: Dobesh PP,Fanikos J

    更新日期:2014-11-01 00:00:00

  • Corticosteroids and adrenal suppression. Characterising and avoiding the problem.

    abstract::Glucocorticoids are used for a variety of illnesses. One of their major complications is suppression of the hypothalamic-pituitary-adrenal axis, rendering a patient unable to respond to stress. The risk of this suppression may be minimised by the use of short-acting glucocorticoid preparations, administration of the e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938050-00008

    authors: Helfer EL,Rose LI

    更新日期:1989-11-01 00:00:00

  • Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.

    abstract::Potassium channel openers or agonists represent a novel new class of compounds in the treatment of a range of cardiovascular disorders, particularly angina pectoris and hypertension. Nicorandil is the only clinically available potassium channel opener with antianginal effects, and with comparable efficacy and tolerabi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161120-00002

    authors: Gomma AH,Purcell HJ,Fox KM

    更新日期:2001-01-01 00:00:00

  • Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.

    abstract:UNLABELLED:Fentanyl is a synthetic opioid agonist which interacts primarily with the mu-opioid receptor. The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for delivery by the transdermal therapeutic system. These patches are designed to deliver fentanyl at a constant rate (25, 50,...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161150-00014

    authors: Muijsers RB,Wagstaff AJ

    更新日期:2001-01-01 00:00:00

  • Epidemiology and therapy of Chlamydia trachomatis infections.

    abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198427050-00005

    authors: Bowie WR

    更新日期:1984-05-01 00:00:00